BioTheranostics Overview

  • Founded
  • 1996
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 131
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $231M
Latest Deal Amount

BioTheranostics General Information

Description

Developer of commercial-stage molecular diagnostics intended to guide cancer treatment. The company develops and commercializes proprietary molecular-based diagnostic, prognostic and predictive tests that provide physicians with actionable information to help to guide cancer treatment, enabling the medical community to optimize clinical decision-making related to oncology.

Contact Information

Formerly Known As
SDL Acquisition, AviaraDX
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Diagnostic Equipment
Other Healthcare Technology Systems
Clinics/Outpatient Services
Parent Company
Primary Office
  • 9640 Towne Centre Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (877) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioTheranostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 22-Feb-2021 $231M 000.00 00000 Completed Generating Revenue
5. Debt - PPP 27-Apr-2020 00.000 000.00 Completed Generating Revenue
4. Later Stage VC 12-Apr-2019 00.000 000.00 Completed Generating Revenue
3. Later Stage VC 21-Jan-2016 0000 0000 0000 Completed Generating Revenue
2. Merger/Acquisition 11-Sep-2008 $60M $8M 0000 Completed Generating Revenue
1. Later Stage VC 19-Nov-2007 $8M $8M 0000 Completed Generating Revenue
To view BioTheranostics’s complete valuation and funding history, request access »

BioTheranostics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000,000 00.000000 000 00.00 00.00 00 00.00 00.000
To view BioTheranostics’s complete cap table history, request access »

BioTheranostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of commercial-stage molecular diagnostics intended to guide cancer treatment. The company develops and commerc
Laboratory Services (Healthcare)
San Diego, CA
131 As of 2021
000.00
0000 0000-00-00
000000&0 000.00

0000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
0000000000000 00000000
Vancouver, Canada
00 As of 0000
00.00
000000&0 00.00

00000000

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000 00000000 (0000000000)
Birmingham, AL
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioTheranostics Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Canexia Health Pending Transaction (M&A) Vancouver, Canada 00 00.00 000000&0 00.00
00000000000 Venture Capital-Backed Birmingham, AL 00 00.000 0000000000 0 00.000
00000000 00 Formerly VC-backed Thousand Oaks, CA 00 000.00 00000000 000.00
00000000 00000000 Formerly VC-backed San Diego, CA 00 000.00 00000000
0000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 000000&0 00000
You’re viewing 5 of 29 competitors. Get the full list »

BioTheranostics Patents

BioTheranostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170137891-A1 Integration of tumor characteristics with breast cancer index Pending 13-Nov-2015 0000000000 0
EP-3374526-A4 Integration of tumor characteristics with breast cancer index Pending 13-Nov-2015 0000000000
EP-3374526-A1 Integration of tumor characteristics with breast cancer index Pending 13-Nov-2015 0000000000
US-10253369-B2 Predicting likelihood of response to combination therapy Active 29-May-2014 0000000000 0
US-20150344967-A1 Predicting likelihood of response to combination therapy Granted 29-May-2014 C12Q1/6886 0
To view BioTheranostics’s complete patent history, request access »

BioTheranostics Executive Team (16)

Name Title Board Seat Contact Info
Gail Sloan Chief Financial Officer
Andy Lavagnino Contract Controller
Matt Sargent Vice President & Chief Commercial Officer
Debra Hadley Vice President, Laboratory Operations
Kevin Thornal Acting Chief Executive Officer
You’re viewing 5 of 16 executive team members. Get the full list »

BioTheranostics Board Members (9)

Name Representing Role Since
David Kabakoff Ph.D HealthQuest Capital Board Member 000 0000
Eric Bednarski Ph.D MVM Partners Board Member 000 0000
You’re viewing 2 of 9 board members. Get the full list »

BioTheranostics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioTheranostics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioMérieux Corporation Majority 000 0000 000000 0
Evidity Health Capital Growth/Expansion Minority 000 0000 000000 0
HealthQuest Capital Growth/Expansion Minority 000 0000 000000 0
MVM Partners Growth/Expansion Minority 000 0000 000000 0
SDL Ventures Venture Capital Minority 000 0000 000000 0
To view BioTheranostics’s complete investors history, request access »